Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CES2 | O00748 | 2/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL5313046 | 1.00 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL165161 | 1.00 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL21647917 | 1.00 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL1050 | 1.00 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL29777368 | 1.00 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL1374278 | 0.97 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL3934174 | 0.97 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL9188111 | 0.97 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL1680817 | 0.97 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL5000945 | 0.97 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1872 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079744-A | Method for resolution of D, L-menthol enantiomer | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079804-A | Production method of high-purity (1R, 2S, 5R) -WS-3 | — | 2026-05-26 | — | — | CN | claimed |
| EP-4265604-B1 | OXASPIRO SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2026-04-01 | — | — | EP | claimed |
| EP-4688761-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Tonix Pharma Limited (IE) | 2026-02-11 | — | — | EP | claimed |
| EP-3568400-B1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-11-19 | — | — | EP | claimed |
| EP-4626904-A1 | MANDELIC ACID SALT OF PALMITOYL LYSYLVALYL-LYSINE | DSM IP Assets B.V. (NL) | 2025-10-08 | — | — | EP | claimed |
| US-20250276974-A1 | PROCESS FOR PREPARING ZANUBRUTINIB IN AMORPHOUS FORM | OLON S.P.A. (IT) | 2025-09-04 | — | — | US | claimed |
| US-20250270361-A1 | CHIRAL METAL OXIDE NANOSTRUCTURE, AND METHOD FOR PRODUCING SAME | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2025-08-28 | — | — | US | claimed |
| CN-119954778-A | Synthesis method of lenacipam sodium and series of intermediate compounds thereof | 杭州科巢生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119275704-B | Continuous wave three-dimensional chiral perovskite laser and preparation method thereof | 浙江大学 | 2025-05-02 | — | — | CN | claimed |
| CN-101389621-A | Method for preparing (S) - (-) -N, N-dimethyl-3- (2-thienyl) -3-hydroxypropyl amine serving as intermediate of duloxetine | TEVA PHARMA (IL) | 2009-03-18 | — | — | CN | claimed |
| CN-100369897-C | Diastereomeric salts of terfenadine | MERRELL PHARMA INC (US) | 2008-02-20 | — | — | CN | claimed |
| CN-1740156-A | Diastereomeric salts of terfenadine | MERRELL PHARMA INC (US) | 2006-03-01 | — | — | CN | claimed |
| US-6756406-B2 | ANTIARTHRITIC AGENTS; RHEUMATIC DISEASES; OSTEOARTHRITIS; INHIBITION OF THE INDUCIBLE NITRIC OXIDE SYNTHASE - INDUCED AFTER ACTIVATION OF VASCULAR SMOOTH MUSCLE, MACROPHAGES, ENDOTHELIAL CELLS BY ENOTOXIN AND CYTOKINES | PHARMACIA CORPORATION | 2004-06-29 | — | — | US | claimed |
| EP-1317416-A2 | 2-AMINO-2-ALKYL-4 HEXENOIC AND HEXYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020128510-A1 | 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2002-09-12 | — | — | US | claimed |
| WO-2002022559-A2 | 2-AMINO-2-ALKYL-4 HEXENOIC AND HEXYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-03-21 | — | — | WO | claimed |
| CN-1309121-A | Method for resolving alpha- [ 4- (1, 1-dimethylethyl) phenyl ] -4- (hydroxydiphenylmethyl) -1-piperidinebutanol and compounds derived therefrom | MERRELL DOW PHARMA (US) | 2001-08-22 | — | — | CN | claimed |
| CN-1293193-A | Preparation of piperidyl amino methyl trifluoro methyl cyclo other compounds | PFIZER PRODUCTS CORP (US) | 2001-05-02 | — | — | CN | claimed |
| CN-1148382-A | Process and diastereomeric salts for optical resolution of racemic alpha- [4- (1, 1-dimethylethyl) phenyl ] -4- (hydroxydiphenylmethyl) -1-piperidinebutanol and compounds derived therefrom | MERRELL DOW PHARMA (US) | 1997-04-23 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276974-A1 | PROCESS FOR PREPARING ZANUBRUTINIB IN AMORPHOUS FORM | ZYX, ABL2, FYN | LMNA 1629/4885MAPK1 781/4885CES2 4598/4885 |
| US-20020128510-A1 | 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | ALOX12, ALOX5, ALOX15 | LMNA 3169/4885MAPK1 1215/4885CES2 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.